Periodic and Aperiodic Alterations of Resting‐State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights
Year: 2025
Type: article
Study design: Observational Study
Abstract: Schizophrenia spectrum disorders (SSD) are marked by cognitive deficits and clinical symptoms linked to disrupted neural oscillations. While changes in spectral power are well documented in SSD, many studies have not clearly separated rhythmic (periodic) from the nonrhythmic (aperiodic) brain activity. This study examined both periodic and aperiodic resting-state EEG components in SSD, recorded from 152 healthy controls and 97 SSD participants. EEG features (periodic power, bandwidth, center frequency; aperiodic exponent and offset) were extracted from global scalp averages and frontoinsular regions, including the dorsal anterior cingulate cortex (dACC), right anterior insula (R-INS), and left anterior insula (L-INS). At the scalp level, SSD individuals exhibited a global increase in theta power, along with a decreased alpha center frequency. Aperiodic activity showed increased exponent and offset in SSD. In frontoinsular regions, increased theta power was observed in the dACC, R-INS, and L-INS, along with lower alpha center frequency in L-INS. No significant differences were found for aperiodic activity in these regions. Increased frontoinsular theta power, especially in the dACC, was associated with worse cognitive performance, particularly global cognition and working memory. These findings highlight the importance of separating periodic and aperiodic EEG activity in SSD, suggesting that periodic alterations, particularly in frontoinsular theta oscillations, may underlie cognitive dysfunction in SSD.
Source: European Journal of Neuroscience
DOI: 10.1111/ejn.70263
Authors: Genc Hasanaj, Iris Jaeger, Berkhan Karsli, Enrico Schulz, Emanuel Boudriot, Lukas Roell, Maxim Korman, Marcel S. Kallweit, Fanny Dengl, Nicole Klimas, Kristin Fischer, Katharina Hanken, Verena Meisinger, Joanna Moussiopoulou, Vladislav Yakimov, Susanne Karch, Alkomiet Hasan, Andrea Schmitt, Peter Falkai, CDP Working Group, Oliver Pogarell, Florian J. Raabe, Elias Wagner, Matin Mortazavi, Daniel Keeser
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,560
Funders: International Max Planck Research School for Environmental, Cellular and Molecular Microbiology, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Ludwig-Maximilians-Universität München, International Max Planck Research School for Advanced Methods in Process and Systems Engineering
Awards: G1807639719, G2395585762, DZPG Aufbauförderung - 'Standort München' - Evidenzbasierte Psychiatrie und Psychotherapie, Neuromodulation, Rekrutierungsplattformen, DZPG Aufbauförderung - 'Standort München' - PPI Strategien und Brückenprojekt zum DZKJ, G4086133564, DZPG Aufbauförderung - 'Standort München': Betriebskonzept, G75627440, GDNF_UpReg - Glial Cell Line-Derived Neurotrophic Factor (GDNF) fördert Schizophrenie: ein vielversprechendes Ziel für eine innovative Behandlung, G8377545079, G8465338680
OpenAlex ID: W4414810795
